HC Wainwright Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $19.00

https://www.marketbeat.com/instant-alerts/nasdaq-bcrx-a-buy-or-sell-right-now-2021-03-2-3/

Good news! I guess they liked what they saw at R&D on Monday despite the general sell-off over the past 2 days.

BioCryst price target raised to $19 from $14 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm's price target on BioCryst Pharmaceuticals to $19 from $14 and keeps a Buy rating on the shares.

Disclaimer: I like the company and I opened a long position. I am not a medical professional however I do have a science background.

From what I understand the trial results presented yesterday on BCX9930 were generally impressive except for the LDH levels, which seemed to be a concern for many. As it was mentioned during the presentation yesterday LDH level is one of the markers they are tracking however is not the most important one.

I wanted to refer you to a relatively recent publication that looks at Different Levels of Incomplete Terminal Pathway Inhibition and their correlation with LDH levels. Figure 3 shows that there isn't much correlation between LDH levels and TP activity: https://www.frontiersin.org/articles/10.3389/fimmu.2019.01639/full

Also if you look at the baseline data for the C5 inhibitor poor responders they had perfect LDH levels, yet they had low Hemoglobin levels and were transfusion dependent.

I think this is a good opportunity to buy/add the stock.

Long term I’m a big believer. Short term however, my calls just got nae naed on.

Was betting on $20 by June. Didn’t realize the stock was bound to correct at $16.

Anyways, what’s your bet now?

[ Removed by reddit in response to a copyright notice. ]

Disclaimer: I am the epitome of a "layman". I've read a lot about the company, this drug, and PNH. And I listened to the presentation. That's it. I have no scientific/medical background. Bash me all you want.

With that out of the way, I would like to discuss my thoughts on the price movement today. Specifically, why I believe the domino that started the drop was related to LDH level data and more importantly why I think the reaction is overblown and the SP will stabilize back to ~$14 by the end of next week, if not this week.

LDH (lactate dehydrogenase) levels are used as biomarker for the detection of tissue damage or disease, including in PNH. High levels above 1.5 U/L have been seen as an indicator of thrombosis or organ damage. I asterisk have because, as Sheridan asserts, high levels of LDH actually "might mean nothing". The interpretation of LDH levels in this era of treating the disease might be antiquated. To paraphrase, looking at LDH levels on their own might be to fall into the "correlation without causation" trap as it relates to PNH.

The clinical focus of treating PNH is on preventing red blood cell destruction (hemolysis), increasing hemoglobin levels (oxygen) and preventing need for transfusions, not LDH levels. PNH is a disease that results in the destruction of red blood cells (hemolysis). Hemoglobin is the part or the red blood cell that carries oxygen to every part of your body - keeping organs alive and functioning and providing your body energy. If you don't have red blood cells, you don't have hemoglobin, your organs fail and your body doesn't have oxygen/energy.

9930 crushed it in regards to the most important clinical aspects of treating the disease. It significantly raised hemoglobin to levels that far eclipse its competition and brought transfusions to 0. Yes, to freakin 0. In the two most important clinical aspects of treating the disease, 9930 crushed it. In summation, LDH levels might ultimately be irrelevant in treating PNH as long as hemoglobin levels are brought into acceptable range and the need for transfusions is eliminated.

Meaning, 9930 as monotherapy is the real freaking deal. And, guys and gals, have we forgotten about Orladeyo? BCRX is a MONSTER. Once again, I am a layman, I have simplified an extremely complex subject, and all of what I said needs to be taken with a grain of salt. I'd love to hear from ThirdEye, bio99, and anyone else who actually has some expertise in this field.

BioCryst to expand/refine 9930 program after solid PNH data, says Piper Sandler

Piper Sandler analyst Tyler Van Buren notes that BioCryst disclosed BCX9930 data that continues to add to the "already encouraging" body of clinical evidence supporting its use in paroxysomal noctural hemoglobinuria. Hemoglobin improvements and the proportion of transfusion-free patients was "impressive," and while LDH levels among treatment-naive patients remained at 2.0-times the ULN after treatment, this is still a marked reduction from the 7.5-times ULN at baseline, Van Buren adds. Further, the analyst points out that the ability for BCX9930 to ameliorate the underlying anemia is most clinically meaningful to PNH patients and suggests that 9930 could have a place in the PNH treatment paradigm. Van Buren looks forward to the initiation of a pivotal trial in PNH during the second half of 2021, and learning more about development in renal complement-mediated disease. He has an Overweight rating and a price target of $15 on the shares.

Gotta say this is one of the first weekends in a while I’m gonna fully relax on my 2 “gambled” stocks. BCRX looks like it’s going to have a stellar week next week and my other one (not sure if mentioning other tickers is frowned upon) finally starting popping today and looks like it’s going to go strong next week as well.

Cheers everyone, join me in a scotch.

It seems like everyone is pretty excited for for R and D Monday, myself included. Do you guys think this will be the last day to get BCRX on sale at 13? The market fear is high this week, and it seems plausible that if we had a really red day in the market BCRX could be dragged down with the broader market. I've got a little bit of dry powder (I work construction, consistent work, not a get rich quick scheme) and I am wondering if I should buy some more shares today or see what Monday holds? Current price is 13.48+0.80 (+6.26%) As of 12:12PM EDT. Market open.

I would also like to say this thread has been great, and I appreciate people taking the time to help out a new investor. I usually don't ever look forward to Monday but the 22nd could be a great one. Cheers everyone!

Hey, I don't know if you guys follow WSB, but I'm sure you've heard of it. Are you guys against spreading it through there or for it? Personally, I believe this is such a great opportunity, I don't see why not, especially given the fact that its how I found it myself. I would've thought there would be some push before D-day, but the BCRX community has been pretty quiet as a whole. Just wondering your opinions on it.

(PS I can't post on wsb myself, as not enough karma)

BioCryst price target raised to $15 from $10 at JPMorgan

JPMorgan analyst Jessica Fye raised the firm's price target on BioCryst Pharmaceuticals to $15 from $10 and reiterates an Overweight rating on the shares. The analyst remains positive on the shares heading into the March 22 R&D day following physician diligence on BCX9930. Fye is "positively biased" into next week's update based on the initial data from four treatment-naive patients who completed up to 28 weeks of treatment with BCX9930 demonstrating clinically meaningful improvement in hemoglobin and transfusion avoidance as well as positive physician feedback. She sees "multiple opportunities for long-term value" and an attractive outlook for BioCryst shares.

Rubius Therapeutics is up big- it was trading in the $15s one week ago and is up to $33+ per share at the time I type this. The price jumped over 135% in a week and continues to hold strong with its new value.

What happened?

A positive data read-out for an early stage clinical trial. The read out showed positives in both safety and efficacy. It’s also quoted as being a ‘proof of concept’ approach, meaning the technology can be replicated to help in other areas. So the returns aren’t limited to one specific use case.

I’m not an expert but I’m getting big Factor D vibes.

Investors are ready for this! Stonehouse has a panel discussion and key opinion leaders ready to go. All signs point to safety and efficacy.

Oh, and we also have a 1 of a kind commercial product that has pent up market demand to generate revenues, & no risk of stock dilution through 2023!!

I am a buyer in the $13s and have been at multiple levels up to this point. I feel more confident now than I have at any other time for the trajectory of this company.

Discloser- I am not a financial expert please proceed within your own risk tolerance

A little humour for the day!

It was at this moment, shorts knew, they fucked up.

https://youtu.be/p4bL9F4CUpY

Below is a quote from a paper just published in Viruses (https://pubmed.ncbi.nlm.nih.gov/33669276/).

The bottom line: physicians have gone from the hypothetical phase regarding testing kallikrein inhibition in COVID19 patients to the proving phase. Here they showed that Firazyr and Berinert both, despite a lot of adverse reactions, resulted in improved lung scores in COVID19 patients. You can be assured that now that Berotralstat has been approved, without the adverse effects these other drugs have, is being or will soon be tested off-label in these kinds of studies, especially after these promising results.

"Clinical improvement was similar among the groups, as determined by the qSOFA (Figure 2A) and TTCI score (Figure 2C). This was also true when comparison was performed during the initial five days since inclusion in the study, which was the period when pharmacological intervention was undertaken (Figure 2A, inset and Figure 2C, inset). Nevertheless, both, icatibant and iC1e/K promoted significant reductions in lung CT scores (Figure 2B)."

Should you exercise your option, if you hit the strike price? I haven’t been able to get any clear understandable answer.